Amgen's gastric cancer drug meets late-stage trial goal
ReutersJun 30, 2025 1:06 PM
June 30 (Reuters) - Amgen AMGN.O said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Circle Stock Price Outlook: Will Circle Internet Group Rebound in 2026?
TradingKey - Circle Internet Group (CRCL) saw its stock price experience a roller coaster ride since its 2025 IPO debut at $31 a share. Those early fireworks faded, and the shares now sit roughly 75% below their June peak, though they’re still more than double the IPO level. Outside of that first-moTradingKey
4 hours ago
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.TradingKey
15 hours ago
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.TradingKey
Tue, Feb 24
